Page 13 - Genentech News Today

Group sales grew by 2%1 at constant exchange rates , driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there...

The event will include a career fair, a movie night and several facility tours, all designed to give residents and job seekers a sense of what biotech is all about and what the field means to Vacaville.

Former Stanford president, Marc Tessier-Lavigne, is the CEO of new biopharma startup, Xaira. The startup already has $1 billion in investments and seeks to use AI to generate molecules to treat diseases.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript April 23, 2024 Kiniksa Pharmaceuticals, Ltd. beats earnings expectations. Reported EPS is $-0.00025, expectations were $-0.14. KNSA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]

Xaira's CEO, Dr. Marc Tessier-Lavigne, resigned as president of Stanford University last August due to controversy over inaccuracies discovered in his lab's scientific papers.

Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The

Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The

These 10 defensive stocks supply investors with reliable earnings, and often dividends, when markets look uncertain.

A new study suggests positron emission tomography (PET) brain scans could reveal hidden inflammation in patients with multiple sclerosis (MS) who are being treated with highly-effective treatments.

Investegate announcements from BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024